Drug intelligence / Profile preview

CGN-003

Development stage: Preclinical
Lead developer: CitraGen Pharmaceuticals
Modality: Small Molecules

Overview

CGN-003 is an investigational drug candidate currently in the preclinical stage of development by CitraGen Pharmaceuticals. It is being developed for the treatment of arthritis pain. As a pipeline asset of a specialty pharmaceutical company that focuses on complex generics and value-added medicines, CGN-003 likely represents a novel formulation or a repurposed therapeutic aimed at improving the management of chronic pain associated with arthritis. However, specific details regarding its chemical structure, biological target, and exact mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on CGN-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGN-003.

Explore the full profile